Royalty Report: Drugs, Pharmaceuticals, Therapeutic – Collection: 709

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 204

License Grant
Licensor hereby grants and agrees to grant to Licensee, until the expiration of the patents, an exclusive, worldwide, non-assignable, License under the Licensed Patents to practice, perform, make, have made, use, sell, import, and offer to sell Licensed Products solely in the Field of Use and to sub-license the Licensed Technology to a third party.
License Property
Licensor owns various proprietary and intellectual property rights including those pertaining to treatment of various clinical conditions such as, but not limited to, diabetes.

Licensed Patents – U.S. Patent Application No. 12/051,373, filed March 19, 2008, entitled “Methods and Compositions for Treating Diabetes” which is a continuation application of Application 09/518,081 filed on March 03, 2000 and Provisional Application No. 60/127,167, filed March 05, 1999

Field of Use
Field of use means solely for treatment of diabetes.

IPSCIO Record ID: 709

License Grant
Licensor grants and agrees to grant to Licensee an exclusive, non-assignable, License under the Licensed Patents (i) to practice, perform, make, have made, use, sell, import, and offer to sell Licensed Products and (ii) to sub-license the Licensed Technology.
License Property
U.S. Patent Application No. 12/051,373, filed March 19, 2008, entitled “Methods and Compositions for Treating Diabetes” which is a continuation application of Application 09/518,081 filed on March 03, 2000 and Provisional Application No. 60/127,167, filed March 05, 1999.
Field of Use
Field of Use  means solely for treatment of diabetes. Field of Use does not include treatment of any complications or secondary clinical conditions related to diabetes, other than Licensee’s Secondary Clinical Conditions.

IPSCIO Record ID: 28926

License Grant
The University grants to Licensee the exclusive license under the Patent Rights to make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the Field of Use. The Licensor also grants to Licensee the rights to issue exclusive or nonexclusive sublicenses. Field of Use means the use of Licensed Products for the treatment, prevention or palliation of any autoimmune disease, condition or indication, including, without limitation, multiple sclerosis.
License Property
The Licensor has conducted clinical trials of Estriol and certain additional intellectual property relating to the subject matter of the License Agreement has been created by the Licensor including the use of estrogens to control fatigue.

1) UCLA CASE NO. 2015-280: “Using Estrogens as Treatment to Improve Fatigue in Multiple Sclerosis and Other Neurodegenerative Diseases”

Provisional Patent Application No. 62/067,264 entitled, “Compositions and Methods for Treating Fatigue”, filed October 22, 2014 (UCLA Case No. 2015-280-1) by Dr. Rhonda R. Voskuhl, and assigned to The Regents.

2) UCLA CASE NO. 2015-282: “Using Estrogens as Treatments to Improve Depression Mood in Multiple Sclerosis and Other Neurodegenerative Diseases”

Provisional Patent Application No. 62/068,162 entitled, “Compositions and Methods for Treating Depression”, filed October 24, 2014 (UCLA Case No. 2015-282-1) by Dr. Rhonda R. Voskuhl, and assigned to The Regents.

3) UCLA CASE NO. 2015-605: “Estriol Blood Level for Maximizing Treatment in MS”

Provisional Patent Application No. 62/140,239 entitled, “Methods of Monitoring Estriol Therapy”, filed October 30, 2014 (UCLA Case No. 2015-605-1) by Dr. Rhonda R. Voskuhl, and assigned to The Regents.

4) UCLA CASE NO. 2015-606-1: “Sparing Gray Matter Atrophy In Ms Patients That Are Enhancing Lesion Negative”

Provisional Patent Application No. 62/140,245 entitled, “Methods of Providing Neuroprotective Therapy”, filed March 30, 2015 (UCLA Case No. 2015-606-1) by Dr. Rhonda R. Voskuhl, and assigned to The Regents.

Field of Use
“Field of Use” means the use of Licensed Products for the treatment, prevention or palliation of any autoimmune disease, condition or indication, including, without limitation, multiple sclerosis.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.